Paper

Cost-Effectiveness of Atorvastatin in the Primary Prevention of Major Cardiovascular Events in Patients with Type 2 Diabetes in Canada

Published 2009 · H. Khoury, M. Wagner, E. Merikle

Canadian Journal of Diabetes

Citations

Influential Citations

Abstract

Abstract removed due to Elsevier request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

Key takeawayAtorvastatin is cost-effective for primary prevention of major cardiovascular events in patients with type 2 diabetes in Canada, with a 1% fewer deaths compared to placebo.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Cost-Effectiveness of Atorvastatin in the Primary Prevention of Major Cardiovascular Events in Patients with Type 2 Diabetes in Canada

References

Citations